159 related articles for article (PubMed ID: 37183427)
1. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction.
Zhang Q; Jiao X; Lai X
J Clin Endocrinol Metab; 2023 Oct; 108(11):2916-2923. PubMed ID: 37183427
[TBL] [Abstract][Full Text] [Related]
2. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
4. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
5. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects.
Iwamoto Y; Kimura T; Dan K; Ohnishi M; Takenouchi H; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1221723. PubMed ID: 37583431
[TBL] [Abstract][Full Text] [Related]
7. The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Ma C; Hodi FS; Giobbie-Hurder A; Wang X; Zhou J; Zhang A; Zhou Y; Mao F; Angell TE; Andrews CP; Hu J; Barroso-Sousa R; Kaiser UB; Tolaney SM; Min L
Cancer Immunol Res; 2019 Jul; 7(7):1214-1220. PubMed ID: 31088848
[TBL] [Abstract][Full Text] [Related]
8. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis.
Yang P; Shen G; Zhang H; Zhang C; Li J; Zhao F; Li Z; Liu Z; Wang M; Zhao J; Zhao Y
Int Immunopharmacol; 2024 May; 133():111961. PubMed ID: 38608442
[TBL] [Abstract][Full Text] [Related]
9. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
10. Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy.
Luongo C; Morra R; Gambale C; Porcelli T; Sessa F; Matano E; Damiano V; Klain M; Schlumberger M; Salvatore D
J Endocrinol Invest; 2021 Sep; 44(9):1927-1933. PubMed ID: 33576954
[TBL] [Abstract][Full Text] [Related]
11. Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients.
Baek HS; Jeong C; Shin K; Lee J; Suh H; Lim DJ; Kang MI; Ha J
BMC Endocr Disord; 2022 Apr; 22(1):89. PubMed ID: 35379219
[TBL] [Abstract][Full Text] [Related]
12. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors.
Inaba H; Ariyasu H; Iwakura H; Kurimoto C; Takeshima K; Morita S; Furuta H; Hotomi M; Akamizu T
Endocr J; 2021 Feb; 68(2):231-241. PubMed ID: 33012745
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
Lin L; Yang F; Lin G; Chen X
J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
[TBL] [Abstract][Full Text] [Related]
14. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
[TBL] [Abstract][Full Text] [Related]
15. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
Lima Ferreira J; Costa C; Marques B; Castro S; Victor M; Oliveira J; Santos AP; Sampaio IL; Duarte H; Marques AP; Torres I
Cancer Immunol Immunother; 2021 Feb; 70(2):299-309. PubMed ID: 32712715
[TBL] [Abstract][Full Text] [Related]
16. Outcomes and Management of Immune Checkpoint Inhibitor-Induced Hypothyroidism: A Retrospective Analysis.
Phillips AL; Reeves DJ
Ann Pharmacother; 2022 Oct; 56(10):1100-1105. PubMed ID: 35168406
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
Yoon JH; Hong AR; Kim HK; Kang HC
Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and risk factors of programmed death-1 inhibitors associated with thyroid gland injury].
Gong WW; Zhou FY; Guo QH
Zhonghua Nei Ke Za Zhi; 2023 Feb; 62(2):176-181. PubMed ID: 36740408
[No Abstract] [Full Text] [Related]
19. Immune Checkpoint Inhibitor-induced Thyroid Disorders: A Single Center Experience.
Patrizio A; Fallahi P; Antonelli A; Ferrari SM
Curr Pharm Des; 2023; 29(4):295-299. PubMed ID: 35593347
[TBL] [Abstract][Full Text] [Related]
20. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
